<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30652749</article-id><article-id pub-id-type="pmc">6326449</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0129</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Expressions of Transforming Growth Factor &#x003b2;<sub>1</sub>
Signaling Cytokines in Aortic Dissection</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Shi-Min</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Hong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><aff id="aff1">
<label>1</label> The First Municipal Hospital of Putian, Teaching Hospital,
Fujian Medical University, Putian, Fujian Province, People's Republic of China.
</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Hong Lin, Longdejing Street, 389,
Chengxiang District, Putian, Fujian Province, People's Republic of China, Zip
Code: 351100. E-mail: <email>linhong0218@126.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Nov-Dec</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2018</year></pub-date><volume>33</volume><issue>6</issue><fpage>597</fpage><lpage>602</lpage><history><date date-type="received"><day>02</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>18</day><month>6</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To demonstrate the underlying mechanisms of aortic dissection compared to
those of coronary artery disease in terms of the transforming growth
factor-beta (TGF-&#x003b2;) signaling pathway.</p></sec><sec><title>Methods</title><p>Twenty consecutive aortic dissection patients and 20 consecutive coronary
artery disease patients undergoing a surgical treatment in this hospital
were enrolled into this study. The aortic tissues were sampled and the
TGF-&#x003b2;<sub>1</sub> and its receptor TGF-&#x003b2; receptor I
(T&#x003b2;RI) were detected by Western blotting assay.</p></sec><sec><title>Results</title><p>TGF-&#x003b2;<sub>1</sub> and T&#x003b2;RI were positively expressed in the
aortic tissues in both groups by Western blotting assay. The expressions of
the two proteins were significantly higher in the aortic tissue of patients
with aortic dissection than in those with coronary artery disease. The
quantitative analyses of the relative gray scales of the proteins disclosed
close correlations between the expressions of TGF-&#x003b2;1 and T&#x003b2;RI
in both the study and control group patients.</p></sec><sec><title>Conclusions</title><p>The aortic remodeling of aortic dissection might differ from that of coronary
artery atherosclerosis concerning the nature, mechanism, mode, and
activities of TGF-&#x003b2; signaling pathway. The development of aortic
dissection could be associated with a significantly enhanced function of
TGF-&#x003b2;<sub>1</sub>/Smad signaling transduction as a result of
aortic remodeling incorporating both vascular injury and repair.</p></sec></abstract><kwd-group><kwd>Aneurysm, Dissecting</kwd><kwd>Coronary Artery Disease</kwd><kwd>Intercellular Signaling Peptides and Proteins</kwd><kwd>Blotting, Western</kwd></kwd-group></article-meta></front><body><table-wrap id="t2" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="20%" span="1"/><col width="80%" span="1"/></colgroup><thead><tr style="background-color:#eaeaea"><th align="left" colspan="2" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>AD</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Aortic dissection</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>Akt</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Protein kinase B</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>CAD</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Coronary artery disease</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>EMT</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Epithelial-to-mesenchymal transition</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>MAPK</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Mitogen-activated protein kinase</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>mRNA</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Messenger ribonucleic acid</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>NmuMG</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Normal murine mammary gland</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>PI3K</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Phosphatidylinositol-3-kinase</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>RNA</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Ribonucleic acid</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>TGF</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Transforming growth factor</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>TGF-&#x003b2;</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Transforming growth factor-beta</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>T&#x003b2;RI</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Transforming growth factor-beta receptor
I</bold></td></tr><tr style="background-color:#eaeaea"><td align="left" rowspan="1" colspan="1"><bold>T&#x003b2;RII</bold></td><td align="left" rowspan="1" colspan="1"><bold>= Transforming growth factor-beta receptor
II</bold></td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Transforming growth factor-beta (TGF-&#x003b2;) is a multi-functional cytokine, which
belongs to the TGF superfamily, signaling through transmembrane serine/threonine
kinase receptors and Smad proteins. It is usually in a non-activated state and
becomes activated when binding to the cell surface receptor, initiating the
intracellular signaling transduction. TGF-&#x003b2; plays its biological roles via
TGF-&#x003b2; receptors I and II (T&#x003b2;RI and T&#x003b2;RII) on the membranous
surface. TGF-&#x003b2; stimulates the production of matrix proteins in vascular
smooth muscle cells and matrix protein synthesis, leading to vascular
remodeling<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>, responsible for aortic aneurysmal formation and
possibly coronary artery disorders<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.</p><p>Aortic dissection (AD) is the most dangerous cardiovascular disease and it is
associated with an extremely high mortality if left without timely diagnosis and
treatment<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. Marfan syndrome is a typical genetic defect with
significant propensity for development of AD<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. It has been noted that endothelial
dysfunction of the aortic wall in Marfan patients is caused by <italic>fibrillin
1</italic> gene mutations, thus leading to aortic wall fragility and
predisposing to AD<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. In Marfan syndrome, the microfibrillar deficiency
would cause inadequate matrix sequestration, with subsequent activation of
TGF-&#x003b2;<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. The increased level of TGF-&#x003b2; is associated
with an upregulation of proteases, such as matrix metalloproteinases, and they are
responsible for the remodeling process of the aortic wall extracellular
matrix<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>TGF-&#x003b2; is an important cytokine involved in the developmental process of heart
and vessels<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. It is upregulated in relation to injury of vascular
walls as a mediator of the fibrotic response, and therefore the upregulation of
TGF-&#x003b2; is a result other than a cause of vascular injury<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. An excessive expression
of TGF-&#x003b2; may also hint the progression of secondary
disorders<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. The plasma TGF-&#x003b2; has obtained noteworthy
attention in recent years as a reliable biomarker for the evaluation of therapeutic
effects of aortic remodeling in Marfan patients<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. However, the mechanisms
that TGF-&#x003b2; signaling regulates during the developmental process of AD and
whether TGF-&#x003b2; is increased in aortic conditions in non-Marfan adults remain
unknown. Moreover, the evaluation of cytokine expression of TGF-&#x003b2;<sub>1</sub>
signaling pathways by Western Blotting assays has not been sufficiently described.
In order to determine the roles of TGF-&#x003b2; as a potential biomarker of AD
development, a prospective study was designed to assess the expression of
TGF-&#x003b2; in the aortic tissues of AD patients in comparison to that of patients
with coronary artery disease (CAD) receiving coronary artery bypass grafting.</p></sec><sec sec-type="methods"><title>METHODS</title><p>Twenty consecutive patients with AD receiving an ascending aorta replacement in this
hospital were included in the study group (AD group). Twenty patients with CAD
referred to this hospital for coronary artery bypass grafting were taken as controls
(CAD group). Totally, 25 patients (including all 20 patients from the AD group and 5
patients from the CAD group) were operated on an urgent basis, and 15 patients of
the CAD group received an elective operation. The patients' information is shown in
<xref rid="t1" ref-type="table">Table 1</xref>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patients&#x02019; demographic data.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="28%" span="1"/><col width="26%" span="1"/><col width="26%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Aortic dissection</th><th align="center" rowspan="1" colspan="1">Coronary artery disease</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Case, n</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender, male/female, n</td><td align="center" rowspan="1" colspan="1">17/3</td><td align="center" rowspan="1" colspan="1">15/5</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, year</td><td align="center" rowspan="1" colspan="1">51.4&#x000b1;8.2</td><td align="center" rowspan="1" colspan="1">58.4&#x000b1;4.6</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking, n</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Alcohol, n</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension, n</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus, n</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal failure, n</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" rowspan="1" colspan="1">Operation, n</td><td align="center" rowspan="1" colspan="1">Aorta replacement, with or without<break/>aortic
valve replacement (20)</td><td align="center" rowspan="1" colspan="1">Off-pump coronary artery bypass (12);<break/>on-pump
coronary artery bypass (8)</td><td align="center" rowspan="1" colspan="1">___</td></tr><tr><td align="left" rowspan="1" colspan="1">Survival rate, %</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">NS</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><p>NS=not significant</p></fn></table-wrap-foot></table-wrap><p>Surgically removed aorta specimens from the patients with AD and from the punch holes
of the ascending aorta of the patients receiving coronary artery bypass grafting
were collected, properly stored, and evaluated quantitatively by Western blotting
assay for TGF-&#x003b2;<sub>1</sub> and T&#x003b2;RI.</p><p>Patients' age and gender did not differ between groups. The aortic tissue specimens
were collected immediately after they were severed from the aorta in patients with
AD. In patients receiving coronary artery bypass grafting, the tiny aortic tissues
measuring 0.2~0.4 cm were taken when the anterior wall of the ascending aorta was
punched. The aortic tissues were stored at -80&#x000ba;C, and then thawed for inspection of
TGF-&#x003b2;<sub>1</sub> and T&#x003b2;RI by Western blotting assay.</p><sec><title>Statistics</title><p>Quantitative data were presented as mean &#x000b1; standard deviation with range
and median values. The intergroup differences were compared by independent
samples t-test. Linear correlations of the relative gray scales between the two
groups were assessed. A two-tailed <italic>P</italic>-value &#x0003c;0.05 was
considered statistically significant.</p></sec><sec><title>Ethics</title><p>This study conforms to the Declaration of Helsinki and it was approved by the
institutional research Ethics Committee board. Informed consent was obtained
from each patient.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>TGF-&#x003b2;<sub>1</sub> and T&#x003b2;RI Expressions</title><p>TGF-&#x003b2;<sub>1</sub> and T&#x003b2;RI were positively expressed in the aortic
tissues of patients of both AD and CAD groups (<xref ref-type="fig" rid="f1">Figure 1</xref>). The TGF-&#x003b2;<sub>1</sub> expression in the aortic
tissue of AD patients was significantly higher than that of CAD patients. The
relative gray scale of the T&#x003b2;RI expression was much higher in AD patients
than in CAD patients; however, no significant difference was reached (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Expressions of transforming growth factor-beta
(TGF-&#x003b2;<sub>1</sub>) and transforming growth factor-beta
receptor I (T&#x003b2;RI) in the aortic tissues of aortic dissection
(AD) and coronary artery disease (CAD) patients as investigated by
Western blotting assay.</p></caption><graphic xlink:href="rbccv-33-06-0597-g01"/></fig>
</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>A comparison between the quantitative relative gray scales of
transforming growth factor-beta (TGF-&#x003b2;<sub>1</sub>) and
transforming growth factor-beta receptor I (T&#x003b2;RI) of the
aortic dissection (AD) and the coronary artery disease (CAD) groups.
*P=0.046.</p></caption><graphic xlink:href="rbccv-33-06-0597-g02"/></fig>
</p></sec><sec><title>Linear Correlations</title><p>There was a direct correlation between TGF-&#x003b2;<sub>1</sub> and T&#x003b2;RI
expressions in the AD group (Y=0.383X + 0.584; r&#x000b2;=0.335, r=0.579,
<italic>P</italic>=0.007); and there was a significant direct correlation
between TGF-&#x003b2;<sub>1</sub> and T&#x003b2;RI expressions in the CAD group
(Y=0.708X + 0.113; r&#x000b2;=0.254, r=0.504, <italic>P</italic>=0.024) (<xref ref-type="fig" rid="f3">Figure 3</xref>). The coefficient was stronger in AD
group than in CAD group.</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Correlations between the relative gray scales by Western blotting
assay: (A) a direct correlation between transforming growth
factorbeta (TGF-&#x003b2;<sub>1</sub>) and transforming growth
factor-beta receptor I (T&#x003b2;RI) in the aortic dissection group;
and (B) a significant direct correlation between
TGF-&#x003b2;<sub>1</sub> and T&#x003b2;RI in the coronary artery
disease group.</p></caption><graphic xlink:href="rbccv-33-06-0597-g03"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The present study revealed that TGF-&#x003b2;<sub>1</sub> and T&#x003b2;RI were
positively expressed in the aortic tissues of AD and CAD patients, with a direct
correlationship between TGF-&#x003b2;<sub>1</sub> and T&#x003b2;RI expressions in
patients of AD and CAD groups. The results illustrated that the aortic wall
remodeling happened in response to atherosclerotic or dissecting insults, and the
close relationships between them revealed the mutual biological effects between the
ligands and the receptors. The disparity of the biomarkers' expressions between the
two groups warranted another approach for the understanding of possible differences
in aortic remodeling fashions between groups in terms of nature, mechanism, mode,
and activities of the TGF signaling.</p><p>The expressions of cytokines of the TGF-&#x003b2; signaling pathway depend on the E3
ubiquitin-protein ligases Smurf1 and Smurf2. Knockdown of endogenous Smurf1 or
Smurf2 by ribonucleic acid (RNA) interference significantly suppressed the
anti-inflammatory effects of TGF-&#x003b2;<sub>1</sub>
<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.
TGF-&#x003b2; is a potent regulator of vascular development and remodeling,
contributing to atherosclerotic process and restenosis by augmenting neointimal
proliferation and collagen accumulation<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. TGF-&#x003b2; could activate the
phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) pathway in normal murine
mammary gland (NmuMG) epithelial cells 30 minutes after treatment, and the
activation reached a peak value at 2 hours<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. It could enhance the activities of
cyclin dependent kinase inhibitors, p15Ink4B and p21Waf1/Cip1<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>]</sup>, thereby influencing
the sensitivity of cell proliferation and apoptosis. TGF-&#x003b2; activates p38
mitogen-activated protein kinase (MAPK), which is essential for TGF-&#x003b2;-induced
apoptosis and for epithelial-to-mesenchymal transition (EMT)<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p><p>TGF-&#x003b2; induces extracellular matrix synthesis and prevents enzymatic breakdown
of the extracellular matrix by activating Smad and upregulating the expressions of
fibronectin and connective tissue growth factor, etc.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. Other pro-fibrotic
factors, such as angiotensin II and advanced glycation end products, might also
activate the Smad signaling pathway via TGF-&#x003b2;-dependent or independent
mechanisms<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>. The Smads show diverse functions based on
different family members. In vascular smooth muscle cells, the overexpression of
Smad7 inhibits the expressions of fibronectin and connective tissue growth factor,
whereas Smad2/3 and Smad4 are for deposition of the extracellular matrix mediated by
TGF-&#x003b2;. Alternatively, Smad2/3 signaling pathway could be activated in a
TGF-&#x003b2; dependent manner 24 hours after stimulating vascular smooth muscle
cells by angiotensin II<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>.</p><p>TGF-&#x003b2; has been identified as a key anti-atherogenic agent due to its
fibrosis-stimulating effects. T&#x003b2;RI is usually expressed in unstable plaques,
whereas T&#x003b2;RII is expressed in normal vessels. A study showed that T&#x003b2;RI
increased by two folds 8 hours after vascular injury, TGF-&#x003b2;<sub>1</sub>
increased by ten folds within 24 hours, and T&#x003b2;RII increased by three
folds<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>. Experimental atherosclerosis was observed to be
accelerated when TGF-&#x003b2;<sub>1</sub> was suppressed<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. However, in advanced
atherosclerosis, TGF-&#x003b2;<sub>1</sub> may behave as a proatherogenic stimulus by
increasing extracellular matrix formation and fibrosis<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>. In such occasions,
TGF-&#x003b2;<sub>1</sub> was likely to lose its anti-atherogenic
effects<sup>[<xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r24" ref-type="bibr">24</xref>]</sup>. Thus, in humans with atherosclerosis, decreased
TGF-&#x003b2;<sub>1</sub> signaling and loss of p27 expression could be
found<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. Attenuated TGF-&#x003b2;<sub>1</sub> signaling and
expressions might be an attribution of vascular aging caused by
atherosclerosis<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup>.</p><p>Enhanced TGF-&#x003b2; signaling transduction and weakened receptor kinase were found
in patients with thoracic aortic aneurysm<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>. Jones et al.<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup> discovered
TGF-&#x003b2; signaling transduction dysfunction in the mouse model of thoracic aorta
aneurysm, and they revealed the inherent close relationships between the expression
of TGF-&#x003b2;/Smads and the phenotype of vascular smooth muscle cells.
TGF-&#x003b2;/Smads play a role in molecular regulation in the reversion of vascular
smooth muscle cells, from a synthetic phenotype to a differentiated
phenotype<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup>. An experiment on injured carotid arterial smooth
muscle cells of Sprague-Dawley rats with the use of reverse transcription-polymerase
chain reaction and Western blotting assays showed that TGF-&#x003b2;<sub>1</sub>
stimulated smooth muscle cell proliferations in a concentration-dependent manner.
The expressions of messenger ribonucleic acid (mRNA) and proteins of
TGF-&#x003b2;<sub>1</sub> and T&#x003b2;RII were much higher in the injured
carotid artery than in the control group. However, no difference was found in the
expressions of T&#x003b2;RI mRNA and protein between the two groups. It illustrated
that after vascular injury, the phenotype of the smooth muscle cells changed with
unusual proliferations, leading to increased synthesis and secretion of
TGF-&#x003b2;<sub>1</sub>. The results verified the functions of
TGF-&#x003b2;<sub>1</sub> in promoting proliferation of the injured smooth muscle
cells depending on various receptor subtypes<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup>.</p><p>It has been reported that TGF-&#x003b2;<sub>1</sub> was unevenly distributed in the
aortic wall of patients with AD and of heart donors: it was expressed the highest in
the media, followed by a higher expression in the intima. Intergroup comparisons
revealed that TGF-&#x003b2;<sub>1</sub> expression in the entire aortic wall, media,
and adventitia were much higher in patients with AD than in heart donor control
subjects<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>. Transgenic mouse models of Marfan syndrome also
disclosed a key role of increased TGF-&#x003b2; signaling in promoting vascular
remodeling, dilation, and aneurysmal formation<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>. Therefore, TGF-&#x003b2; plays a
protective role in controlling excessive activations of monocytes and macrophages,
inhibiting matrix degradation, and promoting survival of the smooth muscle cells of
the aortic media<sup>[<xref rid="r32" ref-type="bibr">32</xref>]</sup>.</p><p>When TGF-&#x003b2;/Smad signaling pathway is interfered with T&#x003b2;RI, angiogenesis
and production of matrix metalloproteinases may be reduced, whereas the non-Smad
dependent pathway depends on T&#x003b2;RI, and may enhance the fibrinolytic function
of the extracellular matrix<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>. It was demonstrated that TGF-&#x003b2; may have
anti-inflammatory and fibrosis-promoting effects, and may also prevent unstable
plaque rupture<sup>[<xref rid="r33" ref-type="bibr">33</xref>]</sup>. The inhibitory effect of T&#x003b2;RII to
TGF-&#x003b2; may promote fibrosis and reduce tissue
inflammation<sup>[<xref rid="r34" ref-type="bibr">34</xref>]</sup>. By using neutralizing antibodies of
TGF-&#x003b2;<sub>1</sub>, &#x003b2;<sub>2</sub>, and &#x003b2;<sub>3</sub> to
block the signaling transduction, there would be an association with an accelerated
atherosclerosis and an unstable plaque phenotype<sup>[<xref rid="r35" ref-type="bibr">35</xref>]</sup>. Although
TGF-&#x003b2;<sub>1</sub> can inhibit proliferation, it may enhance early
immigration of the injured tissue in the mesenchymal cells by increasing the
production of matrix metalloproteinase-1<sup>[<xref rid="r36" ref-type="bibr">36</xref>]</sup>. Animal experiments on Marfan models
showed that activation of TGF-&#x003b2; and the concurrent upregulation of matrix
metalloproteinases seemed to contribute to aortic aneurysm
formation<sup>[<xref rid="r37" ref-type="bibr">37</xref>]</sup>. Pathologically, AD is typically characterized by
medial degeneration, smooth muscle cell depletion, and extracellular matrix
degradation<sup>[<xref rid="r38" ref-type="bibr">38</xref>]</sup>.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>The differential expressions of cytokines of TGF-&#x003b2; signaling pathways
supported the hypotheses of diverse vascular remodeling fashions between AD and CAD.
The aortic remodeling of AD might differ from that of CAD concerning the nature,
mechanism, mode, and activities of TGF signaling pathway. The vascular remodeling
might be a degradation of the extracellular matrix by the upregulation of matrix
metalloproteinases in the aorta of AD patients, while it might be a deposition of
the extracellular matrix in the aorta of CAD patients. The development of AD could
be associated with a significantly enhanced function of TGF-&#x003b2;/Smad signaling
transduction as a result of aortic remodeling incorporating both vascular injury and
repair.</p><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors&#x02019; roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">SMY</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">HL</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at The First Municipal Hospital of Putian, Teaching
Hospital, Fujian Medical University, Putian, Fujian Province, People's Republic
of China.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>JH</given-names></name></person-group><article-title>New progress of transforming growth
factor-&#x000df;</article-title><source>J Med Res</source><year>2007</year><volume>36</volume><issue>1</issue><fpage>103</fpage><lpage>104</lpage></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>GM-CSF contributes to aortic aneurysms resulting from SMAD3
deficiency</article-title><source>J Clin Invest</source><year>2013</year><volume>123</volume><issue>5</issue><fpage>2317</fpage><lpage>2331</lpage><pub-id pub-id-type="pmid">23585475</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weigang</surname><given-names>E</given-names></name><name><surname>Nienaber</surname><given-names>CA</given-names></name><name><surname>Rehders</surname><given-names>TC</given-names></name><name><surname>Ince</surname><given-names>H</given-names></name><name><surname>Vahl</surname><given-names>CF</given-names></name><name><surname>Beyersdorf</surname><given-names>F</given-names></name></person-group><article-title>Management of patients with aortic dissection</article-title><source>Dtsch Arztebl Int</source><year>2008</year><volume>105</volume><issue>38</issue><fpage>639</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">19471632</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westaby</surname><given-names>S</given-names></name></person-group><article-title>Aortic dissection in Marfan's syndrome</article-title><source>Ann Thorac Surg</source><year>1999</year><volume>67</volume><issue>6</issue><fpage>1861</fpage><lpage>1863</lpage><pub-id pub-id-type="pmid">10391327</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benke</surname><given-names>K</given-names></name><name><surname>&#x000c1;gg</surname><given-names>B</given-names></name><name><surname>Szilveszter</surname><given-names>B</given-names></name><name><surname>Tarr</surname><given-names>F</given-names></name><name><surname>Nagy</surname><given-names>ZB</given-names></name><name><surname>P&#x000f3;los</surname><given-names>M</given-names></name><etal/></person-group><article-title>The role of transforming growth factor-beta in Marfan
syndrome</article-title><source>Cardiol J</source><year>2013</year><volume>20</volume><issue>3</issue><fpage>227</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">23788295</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dietz</surname><given-names>HC</given-names></name></person-group><article-title>2006 Curt Stern Award Address: Marfan syndrome: from molecules to
medicines</article-title><source>Am J Hum Genet</source><year>2007</year><volume>81</volume><issue>4</issue><fpage>662</fpage><lpage>667</lpage><pub-id pub-id-type="pmid">20529617</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booms</surname><given-names>P</given-names></name><name><surname>Pregla</surname><given-names>R</given-names></name><name><surname>Ney</surname><given-names>A</given-names></name><name><surname>Barthel</surname><given-names>F</given-names></name><name><surname>Reinhardt</surname><given-names>DP</given-names></name><name><surname>Pletschacher</surname><given-names>A</given-names></name><etal/></person-group><article-title>RGD-containing fibrillin-1 fragments upregulate matrix
metalloproteinase expression in cell culture: a potential factor in the
pathogenesis of the Marfan syndrome</article-title><source>Hum Genet</source><year>2005</year><volume>116</volume><issue>1-2</issue><fpage>51</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">15517394</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sridurongrit</surname><given-names>S</given-names></name><name><surname>Larsson</surname><given-names>J</given-names></name><name><surname>Schwartz</surname><given-names>R</given-names></name><name><surname>Ruiz-Lozano</surname><given-names>P</given-names></name><name><surname>Kaartinen</surname><given-names>V</given-names></name></person-group><article-title>Signaling via the TGF-beta type I receptor Alk5 in heart
development</article-title><source>Dev Biol</source><year>2008</year><volume>322</volume><issue>1</issue><fpage>208</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">18718461</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franken</surname><given-names>R</given-names></name><name><surname>Radonic</surname><given-names>T</given-names></name><name><surname>den Hartog</surname><given-names>AW</given-names></name><name><surname>Groenink</surname><given-names>M</given-names></name><name><surname>Pals</surname><given-names>G</given-names></name><name><surname>van Eijk</surname><given-names>M</given-names></name><etal/><collab>COMPARE study group</collab></person-group><article-title>The revised role of TGF-&#x000df; in aortic aneurysms in Marfan
syndrome</article-title><source>Neth Heart J</source><year>2015</year><volume>23</volume><issue>2</issue><fpage>116</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">25342281</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matt</surname><given-names>P</given-names></name><name><surname>Schoenhoff</surname><given-names>F</given-names></name><name><surname>Habashi</surname><given-names>J</given-names></name><name><surname>Holm</surname><given-names>T</given-names></name><name><surname>Van Erp</surname><given-names>C</given-names></name><name><surname>Loch</surname><given-names>D</given-names></name><etal/><collab>GenTAC Consortium</collab></person-group><article-title>Circulating transforming growth factor-beta in Marfan
syndrome</article-title><source>Circulation</source><year>2009</year><volume>120</volume><issue>6</issue><fpage>526</fpage><lpage>532</lpage><pub-id pub-id-type="pmid">19635970</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Jung</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Smad6-specific recruitment of Smurf E3 ligases mediates
TGF-&#x000df;1-induced degradation of MyD88 in TLR4
signalling</article-title><source>Nat Commun</source><year>2011</year><volume>2</volume><fpage>460</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">21897371</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bobik</surname><given-names>A</given-names></name></person-group><article-title>Transforming growth factor-betas and vascular
disorders</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2006</year><volume>26</volume><issue>8</issue><fpage>1712</fpage><lpage>1720</lpage><pub-id pub-id-type="pmid">16675726</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakin</surname><given-names>AV</given-names></name><name><surname>Tomlinson</surname><given-names>AK</given-names></name><name><surname>Bhowmick</surname><given-names>NA</given-names></name><name><surname>Moses</surname><given-names>HL</given-names></name><name><surname>Arteaga</surname><given-names>CL</given-names></name></person-group><article-title>Phosphatidylinositol 3-kinase function is required for
transforming growth factor &#x000df;-mediated epithelial to mesenchymal
1transition and cell migration</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><issue>47</issue><fpage>36803</fpage><lpage>36810</lpage><pub-id pub-id-type="pmid">10969078</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennler</surname><given-names>S</given-names></name><name><surname>Itoh</surname><given-names>S</given-names></name><name><surname>Vivien</surname><given-names>D</given-names></name><name><surname>ten Dijke</surname><given-names>P</given-names></name><name><surname>Huet</surname><given-names>S</given-names></name><name><surname>Gauthier</surname><given-names>JM</given-names></name></person-group><article-title>Direct binding of Smad3 and Smad4 to critical
TGF&#x000df;-inducible elements in the promoter of human plasminogen
activator inhibitor-type 1 gene</article-title><source>EMBO J</source><year>1998</year><volume>17</volume><issue>11</issue><fpage>3091</fpage><lpage>3100</lpage><pub-id pub-id-type="pmid">9606191</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakefield</surname><given-names>LM</given-names></name><name><surname>Roberts</surname><given-names>AB</given-names></name></person-group><article-title>TGF-&#x000df; signaling: positive and negative effects on
tumorigenesis</article-title><source>Curr Opin Genet Dev</source><year>2002</year><volume>12</volume><issue>1</issue><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">11790550</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>H&#x000e9;bert</surname><given-names>MC</given-names></name><name><surname>Zhang</surname><given-names>YE</given-names></name></person-group><article-title>TGF-&#x000df; receptor-activated p38 MAP kinase mediates
Smad-independent TGF-&#x000df; responses</article-title><source>EMBO J</source><year>2002</year><volume>21</volume><issue>14</issue><fpage>3749</fpage><lpage>3759</lpage><pub-id pub-id-type="pmid">12110587</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ihn</surname><given-names>H</given-names></name></person-group><article-title>Pathogenesis of fibrosis: role of TGF-&#x000df; and
CTGF</article-title><source>Curr Opin Rheumatol</source><year>2002</year><volume>14</volume><issue>6</issue><fpage>681</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">12410091</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>HY</given-names></name></person-group><article-title>Diverse roles of TGF-&#x000df;/Smads in renal fibrosis and
inflammation</article-title><source>Int J Biol Sci</source><year>2011</year><volume>7</volume><issue>7</issue><fpage>1056</fpage><lpage>1067</lpage><pub-id pub-id-type="pmid">21927575</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>XH</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name></person-group><article-title>Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B)
transcription in response to TGF-&#x000df;</article-title><source>EMBO J</source><year>2000</year><volume>19</volume><issue>19</issue><fpage>5178</fpage><lpage>5193</lpage><pub-id pub-id-type="pmid">11013220</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WB</given-names></name><name><surname>Lenschow</surname><given-names>W</given-names></name><name><surname>Tiede</surname><given-names>K</given-names></name><name><surname>Fischer</surname><given-names>JW</given-names></name><name><surname>Kalthoff</surname><given-names>H</given-names></name><name><surname>Ungefroren</surname><given-names>H</given-names></name></person-group><article-title>Smad4/DPC4-dependent regulation of biglycan gene expression by
transforming growth factor-&#x000df; in pancreatic tumor
cells</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><issue>39</issue><fpage>36118</fpage><lpage>36128</lpage><pub-id pub-id-type="pmid">12140283</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutgens</surname><given-names>E</given-names></name><name><surname>Gijbels</surname><given-names>M</given-names></name><name><surname>Smook</surname><given-names>M</given-names></name><name><surname>Heeringa</surname><given-names>P</given-names></name><name><surname>Gotwals</surname><given-names>P</given-names></name><name><surname>Koteliansky</surname><given-names>VE</given-names></name><etal/></person-group><article-title>Transforming growth factor-&#x000df; mediates balance between
inflammation and fibrosis during plaque progression</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2002</year><volume>22</volume><issue>6</issue><fpage>975</fpage><lpage>982</lpage><pub-id pub-id-type="pmid">12067907</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strippoli</surname><given-names>R</given-names></name><name><surname>Benedicto</surname><given-names>I</given-names></name><name><surname>Perez Lozano</surname><given-names>ML</given-names></name><name><surname>Pellinen</surname><given-names>T</given-names></name><name><surname>Sandoval</surname><given-names>P</given-names></name><name><surname>Lopez-Cabrera</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inhibition of transforming growth factor-activated kinase 1
(TAK1) blocks and reverses epithelial to mesenchymal transition of
mesothelial cells</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>2</issue><elocation-id>e31492</elocation-id><pub-id pub-id-type="pmid">22384029</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redondo</surname><given-names>S</given-names></name><name><surname>Navarro-Dorado</surname><given-names>J</given-names></name><name><surname>Ramajo</surname><given-names>M</given-names></name><name><surname>Medina</surname><given-names>&#x000da;</given-names></name><name><surname>Tejerina</surname><given-names>T</given-names></name></person-group><article-title>The complex regulation of TGF-&#x000df; in cardiovascular
disease</article-title><source>Vasc Health Risk Manag</source><year>2012</year><volume>8</volume><fpage>533</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">23028232</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grainger</surname><given-names>DJ</given-names></name></person-group><article-title>Transforming growth factor &#x000df; and atherosclerosis: so far,
so good for the protective cytokine hypothesis</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2004</year><volume>24</volume><issue>3</issue><fpage>399</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">14699019</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ihling</surname><given-names>C</given-names></name><name><surname>Technau</surname><given-names>K</given-names></name><name><surname>Gross</surname><given-names>V</given-names></name><name><surname>Schulte-M&#x000f6;nting</surname><given-names>J</given-names></name><name><surname>Zeiher</surname><given-names>AM</given-names></name><name><surname>Schaefer</surname><given-names>HE</given-names></name></person-group><article-title>Concordant upregulation of type II-TGF-&#x000df;-receptor, the
cyclin-dependent kinases inhibitor P27Kip1 and cyclin E in human
atherosclerotic tissue: implications for lesion cellularity</article-title><source>Atherosclerosis</source><year>1999</year><volume>144</volume><issue>1</issue><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">10381272</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redondo</surname><given-names>S</given-names></name><name><surname>Navarro-Dorado</surname><given-names>J</given-names></name><name><surname>Ramajo</surname><given-names>M</given-names></name><name><surname>Medina</surname><given-names>&#x000da;</given-names></name><name><surname>Molina-Sanchez</surname><given-names>P</given-names></name><name><surname>Garces</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Age-dependent defective TGF-beta1 signaling in patients
undergoing coronary artery bypass grafting</article-title><source>J Cardiothorac Surg</source><year>2014</year><volume>9</volume><fpage>24</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">24495866</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>JA</given-names></name><name><surname>Spinale</surname><given-names>FG</given-names></name><name><surname>Ikonomidis</surname><given-names>JS</given-names></name></person-group><article-title>Transforming growth factor-beta signaling in thoracic aortic
aneurysm development: a paradox in pathogenesis</article-title><source>J Vasc Res</source><year>2009</year><volume>46</volume><issue>2</issue><fpage>119</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">18765947</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>CH</given-names></name><name><surname>Shen</surname><given-names>JL</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>BQ</given-names></name><name><surname>Zhe</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>GY</given-names></name><etal/></person-group><article-title>Proliferation of vascular smooth muscle cell and the expression
of transforming growth factor &#x000df;/Smads</article-title><source>Chin J Clin Rehabil</source><year>2005</year><volume>9</volume><issue>19</issue><fpage>50</fpage><lpage>52</lpage></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>ZH</given-names></name><name><surname>Wu</surname><given-names>KG</given-names></name><name><surname>Li</surname><given-names>GS</given-names></name><name><surname>Xie</surname><given-names>LD</given-names></name><name><surname>Lin</surname><given-names>PH</given-names></name></person-group><article-title>Role of transforming growth factor &#x000df;1 and its receptor in
the intimal hyperplasia after vascular injury</article-title><source>Chin J Gerontol</source><year>2015</year><volume>35</volume><issue>8</issue><fpage>2200</fpage><lpage>2202</lpage></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>SG</given-names></name><name><surname>Wang</surname><given-names>CS</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>SJ</given-names></name><name><surname>Hong</surname><given-names>T</given-names></name><name><surname>Lai</surname><given-names>H</given-names></name></person-group><article-title>TGF-&#x000df;1 expression and distribution in the extracellular
matrix of the dissected wall of thoracic aorta</article-title><source>Chin J Thorac Cardiovasc Surg</source><year>2010</year><volume>26</volume><issue>1</issue><fpage>33</fpage><lpage>36</lpage></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habashi</surname><given-names>JP</given-names></name><name><surname>Judge</surname><given-names>DP</given-names></name><name><surname>Holm</surname><given-names>TM</given-names></name><name><surname>Cohn</surname><given-names>RD</given-names></name><name><surname>Loeys</surname><given-names>BL</given-names></name><name><surname>Cooper</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse
model of Marfan syndrome</article-title><source>Science</source><year>2006</year><volume>312</volume><issue>5770</issue><fpage>117</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">16601194</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ait-Oufella</surname><given-names>H</given-names></name><name><surname>Herbin</surname><given-names>O</given-names></name><name><surname>Bonnin</surname><given-names>P</given-names></name><name><surname>Ramkhelawon</surname><given-names>B</given-names></name><name><surname>Taleb</surname><given-names>S</given-names></name><etal/></person-group><article-title>TGF-&#x000df; activity protects against inflammatory aortic
aneurysm progression and complications in angiotensin II-infused
mice</article-title><source>J Clin Invest</source><year>2010</year><volume>120</volume><issue>2</issue><fpage>422</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">20101093</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobson</surname><given-names>KG</given-names></name><name><surname>Cho</surname><given-names>K</given-names></name><name><surname>Adamson</surname><given-names>LK</given-names></name><name><surname>Greenhalgh</surname><given-names>DG</given-names></name></person-group><article-title>Burn-induced thymic apoptosis corresponds with altered
TGF-&#x000df;1 and Smad 2/3</article-title><source>J Surg Res</source><year>2002</year><volume>105</volume><issue>1</issue><fpage>4</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12069494</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Oakley</surname><given-names>J</given-names></name><name><surname>McGee</surname><given-names>EA</given-names></name></person-group><article-title>Stage-specific expression of Smad2 and Smad3 during
folliculogenesis</article-title><source>Biol Reprod</source><year>2002</year><volume>66</volume><issue>6</issue><fpage>1571</fpage><lpage>1578</lpage><pub-id pub-id-type="pmid">12021033</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>AK</given-names></name><name><surname>Rudling</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Gorelik</surname><given-names>L</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group><article-title>Disruption of TGF-&#x000df; signaling in T cells accelerates
atherosclerosis</article-title><source>J Clin Invest</source><year>2003</year><volume>112</volume><issue>9</issue><fpage>1342</fpage><lpage>1350</lpage><pub-id pub-id-type="pmid">14568988</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gugjoo</surname><given-names>MB</given-names></name><name><surname>Amarpal</surname></name><name><surname>Abdelbaset-Ismail</surname><given-names>A</given-names></name><name><surname>Aithal</surname><given-names>HP</given-names></name><name><surname>Kinjavdekar</surname><given-names>P</given-names></name><name><surname>Pawde</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Mesenchymal stem cells with IGF-1 and TGF- &#x000df;1 in laminin
gel for osteochondral defects in rabbits</article-title><source>Biomed Pharmacother</source><year>2017</year><volume>93</volume><fpage>1165</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">28738525</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>W</given-names></name><name><surname>Meisinger</surname><given-names>T</given-names></name><name><surname>Knispel</surname><given-names>R</given-names></name><name><surname>Worth</surname><given-names>JM</given-names></name><name><surname>Baxter</surname><given-names>BT</given-names></name></person-group><article-title>MMP-2 regulates Erk1/2 phosphorylation and aortic dilatation in
Marfan syndrome</article-title><source>Circ Res</source><year>2012</year><volume>110</volume><issue>12</issue><fpage>e92</fpage><lpage>e101</lpage><pub-id pub-id-type="pmid">22550139</pub-id></element-citation></ref><ref id="r38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Shen</surname><given-names>YH</given-names></name><name><surname>Russell</surname><given-names>L</given-names></name><name><surname>Coselli</surname><given-names>JS</given-names></name><name><surname>LeMaire</surname><given-names>SA</given-names></name></person-group><article-title>Molecular mechanisms of thoracic aortic
dissection</article-title><source>J Surg Res</source><year>2013</year><volume>184</volume><issue>2</issue><fpage>907</fpage><lpage>924</lpage><pub-id pub-id-type="pmid">23856125</pub-id></element-citation></ref></ref-list></back></article>